# OnCo record janux-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/janux-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "janux-therapeutics" ;
  schema:name "Janux Therapeutics"@en ;
  schema:description "Janux makes 'masked' T-cell engager antibodies that stay inactive in the bloodstream and switch on only inside tumours, aiming to cut the side effects that limit this drug class. Its lead programmes target PSMA in advanced prostate cancer."@en ;
  schema:url <https://onco.cc/companies/janux-therapeutics/>, <https://www.januxrx.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.januxrx.com/>, <https://www.sec.gov/Archives/edgar/data/1817713/000119312526337977/janx-ex99_1.htm>, <https://www.sec.gov/Archives/edgar/data/1817713/000119312521191155/d177137dex991.htm> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/psma/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/cd19/> .